



# Total Synthesis of Rapamycin

Mathew L. Maddess, Miles N. Tackett, Hidenori Watanabe, Paul E. Brennan, Christopher D. Spilling, James S. Scott, David P. Osborn, Steven V. Ley\*


ACIE 2007, 46, 591–597 (et al. CEJ 2009, 15, 2874–2914)



1-11



12-13



22-34

- 1)  $\text{Ti}(\text{O}i\text{-Pr})_4$ , (+)-DET, *t*-BuOOH,  $\text{CH}_2\text{Cl}_2$ ,  $-25\text{ }^\circ\text{C}$
- 2)  $\text{py}\cdot\text{SO}_3$ ,  $\text{Et}_3\text{N}$ , DMSO,  $\text{CH}_2\text{Cl}_2$ ,  $0\text{ }^\circ\text{C}$  to rt
- 3) LiCl,  $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{CO}_2\text{Me}$ , DBU, MeCN, rt
- 4) DIBAL-H,  $\text{CH}_2\text{Cl}_2$ ,  $-78\text{ }^\circ\text{C}$
- 5)  $\text{Ti}(\text{O}i\text{-Pr})_4$ , (-)-DET, *t*-BuOOH, 4-Å M.S.,  $\text{CH}_2\text{Cl}_2$ ,  $-23\text{ }^\circ\text{C}$
- 6) *cat.* TPAP, NMO,  $\text{CH}_2\text{Cl}_2/\text{MeCN}$ , 4-Å M.S.
- 7)  $\text{MePPh}_3\text{Br}$ , KHMDS, THF,  $0\text{ }^\circ\text{C}$  to rt
- 8)  $\text{Fe}_2(\text{CO})_9$ , degassed THF
- 9) CO, 280 atm., PhH, 2 days
- 10) Adam's catalyst,  $\text{H}_2$ , 1 atm, EtOAc, rt
- 11) LDA, THF,  $-78\text{ }^\circ\text{C}$ ; MeI  
d.r. = 60:40

- 12) DIBAL-H, PhMe,  $-78\text{ }^\circ\text{C}$
- 13) TBSCl, ImH, *cat.* DMAP, DMF, rt
- 14) Pearlman's catalyst,  $\text{H}_2$ , EtOAc, rt
- 15) *cat.* TPAP, NMO,  $\text{CH}_2\text{Cl}_2/\text{MeCN}$ , 4-Å M.S.
- 16)  $\text{MeMgBr}$ ,  $\text{Et}_2\text{O}$ , THF,  $-78\text{ }^\circ\text{C}$
- 17) *cat.* TPAP, NMO,  $\text{CH}_2\text{Cl}_2/\text{MeCN}$ , 4-Å M.S.
- 18)  $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{CN}$ , NaHMDS, THF,  $0\text{ }^\circ\text{C}$ ; **substrate**,  $-78\text{ }^\circ\text{C}$
- 19) DIBAL-H, PhMe,  $-78\text{ }^\circ\text{C}$
- 20) TBAF, AcOH/ $\text{H}_2\text{O}$ /THF, rt
- 21)  $\text{CrCl}_2$ ,  $\text{CHI}_3$ , THF/dioxane,  $0\text{ }^\circ\text{C}$

- 22) TBSCl, ImH,  $\text{CH}_2\text{Cl}_2$ ,  $0\text{ }^\circ\text{C}$  to rt
- 23)  $\text{K}_2\text{CO}_3$ , MeOH, rt
- 24) NaH, PMBCl, *cat.* TBAI, THF,  $0\text{ }^\circ\text{C}$  to rt
- 25) TBAF, THF,  $0\text{ }^\circ\text{C}$
- 26)  $\text{py}\cdot\text{SO}_3$ , DIPEA, DMSO,  $\text{CH}_2\text{Cl}_2$ , rt
- 27) **2**, LiHMDS,  $-78\text{ }^\circ\text{C}$ ; **substrate**,  $-78\text{ }^\circ\text{C}$ ; AcOH,  $-78\text{ }^\circ\text{C}$  to rt

1), 2), 3), 6), 21) Name reactions?

*Sharpless asymmetric epoxidation*


*Parikh--Doering oxidation*

*Horner--Wadsworth--Emmons olefination*

*Ley--Griffith oxidation*


*Takai olefination (Evans--Black modification)*

Suggest a more reliable route to **A** with better stereocontrol, installing the problematic stereocentre with **1**.




12/13, 19/20) Why reduce/ protect C-10 of lactone to reoxidize later?


C-11 epimerizes under these reaction conditions





From which commodity chemical is **2** derived? Explain the observed stereoselectivity for the Aldol addition (name model).

Glycolic acid and Felkin--Anh






↓  
35-39




- 28) PMBTCA, *cat.* TrBF<sub>4</sub>, THF, rt  
 29) (±)-CSA, MeOH, rt  
 30) Ag<sub>2</sub>O, CH<sub>3</sub>I, CH<sub>2</sub>Cl<sub>2</sub>, 50 °C  
 31) LiHMDS, MeO(Me)NH.HCl, -20 °C;  
**substrate**, -20 °C to -10 °C  
 32) **3**, *t*-BuLi, -100 °C; **substrate**, -100 °C to -78 °C  
 33) Zn(BH<sub>4</sub>)<sub>2</sub>, Et<sub>2</sub>O, -20 °C, 2 days  
 34) TESCl, ImH, DMF, 50 °C
- 35) **4**, *t*-BuLi, THF/HMPA (9:1), -78 °C to -40 °C  
 36) PIFA, THF/MeOH/H<sub>2</sub>O (10:9:1), rt  
 37) **5**, DCC, *cat.* DMAP, CH<sub>2</sub>Cl<sub>2</sub>, -5 °C, 24 h  
 38) DDQ, pH 7 buffer, CH<sub>2</sub>Cl<sub>2</sub>, rt  
 39) (COCl)<sub>2</sub>, DMSO, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>
- 40) CrCl<sub>2</sub>, CHI<sub>3</sub>, THF, 0 °C to rt  
 41) *cat.* [Pd(PFur<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>], (Me<sub>3</sub>Sn)<sub>2</sub>, NMP, dark, rt  
 42) **B**, *cat.* [Pd(PFur<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>], (Me<sub>3</sub>Sn)<sub>2</sub>, NMP, dark, rt  
 43) LiAlH(Ot-Bu)<sub>3</sub>, THF, -5 °C  
 44) Alloc-Cl, 4-pyrrolidinopyridine, CH<sub>2</sub>Cl<sub>2</sub>  
 45) 0.1 M aq. LiOH, THF, 5 °C M  
 45) TESOTf, 2,6-lut, CH<sub>2</sub>Cl<sub>2</sub>, -20 °C to rt  
 46) BrCH<sub>2</sub>CO<sub>2</sub>Br, 2,6-lut, CH<sub>2</sub>Cl<sub>2</sub>, -20 °C  
 47) catechol, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt  
 48) K<sub>2</sub>CO<sub>3</sub>, DMF, rt  
 49) LiHMDS, THF, -78 °C to -20 °C  
 50) [Pd(PPh<sub>3</sub>)<sub>4</sub>], dimedone, THF, rt  
 51) PIDA, MeCN/H<sub>2</sub>O (10:1), 0 °C  
 52) DMP, py, CH<sub>2</sub>Cl<sub>2</sub>, rt,  
 53) HF.py, THF, 50 °C

How would you make **3** from Roche ester (and which enantiomer)? see *CEJ* 2009, 15, 2874–2914



33) Stereochemical model





47-49) !? What are they trying to achieve? How otherwise might this be done?

Macrocyclization (Dieckmann architecture)  
 Amide formation

50) What is the role of dimedone?

Nucleophile and regenerates Pd catalyst  
 see *ACIE* 2012, 51, 8648-8651



TL 1994, 35, 2095–2098

- 1)  $\text{Ti}(\text{O}i\text{-Pr})_4$ , (+)-DET, *t*-BuOOH,  $\text{CH}_2\text{Cl}_2$ ,  $-25\text{ }^\circ\text{C}$
- 2)  $\text{py}\cdot\text{SO}_3$ ,  $\text{Et}_3\text{N}$ , DMSO,  $\text{CH}_2\text{Cl}_2$ ,  $0\text{ }^\circ\text{C}$  to rt
- 3)  $\text{MePPh}_3\text{Br}$ , KHMDS, THF,  $0\text{ }^\circ\text{C}$  to rt
- 4) DIBAL-H, PhMe,  $-78\text{ }^\circ\text{C}$
- 5) *n*-BuLi,  $\text{Et}_2\text{O}$ ; BOC-ON, THF, rt
- 6) IBr, PhMe,  $\text{CH}_2\text{Cl}_2$ ,  $-85\text{ }^\circ\text{C}$  to rt
- 7)  $\text{K}_2\text{CO}_3$ , MeOH, rt
- 8) MeI,  $\text{Ag}_2\text{O}$ , DMF, rt
- 9) **1**, *n*-BuLi, THF,  $-78\text{ }^\circ\text{C}$ ; substrate,  $\text{BF}_3\cdot\text{Et}_2\text{O}$ , THF,  $-78\text{ }^\circ\text{C}$  to rt
- 10) 1 M Lithium naphthalenide, THF,  $-90\text{ }^\circ\text{C}$
- 11) DDQ,  $\text{CH}_2\text{Cl}_2$ ,  $\text{H}_2\text{O}$ , rt
- 12) *cat.* TPAP, NMO,  $\text{CH}_2\text{Cl}_2$ , 4-Å M.S.

Suggest a more reliable route to **A** with better stereocontrol

